Uscom Half Yearly Report FY22
Uscom Half Yearly Report FY22
Uscom’s results for H1 FY22 are healthy considering the global headwinds, and despite falling short of our forecasts. The half has been a challenge characterised by an unpredictable and unprecedented global pandemic, with the superimposed complications of Australia’s geopolitical excursions into China and SE Asia. Regardless, our results demonstrate a resilient performance with healthy sales and sales pipelines, and significant cash reserves. Further our growth strategy is sound, and is in mid execution. Our new Asian focused strategy shifts Uscom into the epicentre of the world’s fastest growing economies, equipped with an expanding quiver of sector leading cardiovascular and pulmonary technologies, positioning Uscom perfectly for the predicted growth in these regions over the foreseeable years.